{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:47:32Z","timestamp":1785235652605,"version":"3.55.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100016387","name":"Grifols","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10875-025-01952-5","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:02:03Z","timestamp":1762912923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly\/Biweekly Dosing in Treatment-Experienced Patients and Loading\/Weekly Maintenance Dosing in Treatment-Na\u00efve Patients with Primary Immunodeficiency"],"prefix":"10.1007","volume":"45","author":[{"given":"William R.","family":"Lumry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iftikhar","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. James","family":"Wedner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Scarupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Mondou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Nanaware-Kharade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse Querolt","family":"Coll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Oliveras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"2","key":"1952_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1056\/NEJM199107113250207","volume":"325","author":"RH Buckley","year":"1991","unstructured":"Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. New Engl J Med. 1991;325(2):110\u20137.","journal-title":"New Engl J Med"},{"issue":"2","key":"1952_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00063030-200721020-00005","volume":"21","author":"A Gardulf","year":"2007","unstructured":"Gardulf A. Immunoglobulin treatment for primary sntibody deficiencies. BioDrugs. 2007;21(2):105\u201316.","journal-title":"BioDrugs"},{"issue":"4","key":"1952_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.12968\/hmed.2007.68.4.206","volume":"68","author":"M Helbert","year":"2007","unstructured":"Helbert M, Farragher A. Subcutaneous immunoglobulin for patients with antibody deficiency. Br J Hosp Med. 2007;68(4):206\u201310.","journal-title":"Br J Hosp Med"},{"issue":"4","key":"1952_CR4","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1067\/mai.2001.118640","volume":"108","author":"RA Sacher","year":"2001","unstructured":"Sacher RA. Intravenous Immunoglobulin consensus statement. J Allergy Clin Immunol. 2001;108(4):S139\u201346.","journal-title":"J Allergy Clin Immunol"},{"issue":"1Part1","key":"1952_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/0003-4819-93-1-55","volume":"93","author":"M Berger","year":"1980","unstructured":"Berger M, Cupps TR, Fauci AS. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med. 1980;93(1Part1):55\u20136.","journal-title":"Ann Intern Med"},{"issue":"8273","key":"1952_CR6","first-page":"689","volume":"1","author":"JJ Roord","year":"1982","unstructured":"Roord JJ, van der Meer JW, Kuis W, de Windt GE, Zegers BJ, van Furth R, et al. Home treatment in patients with antibody deficiency by slow subcutaneous infusion of gammaglobulin. Lancet. 1982;1(8273):689\u201390.","journal-title":"Lancet"},{"issue":"8265","key":"1952_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S0140-6736(82)90793-0","volume":"319","author":"AG Ugazio","year":"1982","unstructured":"Ugazio AG, Duse M, Re R, Mangili G, Burgio GR. Subcutaneous infusion of gammaglobulins in management of agammaglobulinemia. Lancet. 1982;319(8265):226.","journal-title":"Lancet"},{"issue":"3","key":"1952_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/BF00915353","volume":"3","author":"M Welch","year":"1983","unstructured":"Welch M, Stiehm ER. Slow subcutaneous immunoglobulin therapy in a patient with reactions to intramuscular immunoglobulin. J Clin Immunol. 1983;3(3):285\u20136.","journal-title":"J Clin Immunol"},{"issue":"8760","key":"1952_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/0140-6736(91)90147-H","volume":"338","author":"A Gardulf","year":"1991","unstructured":"Gardulf A, Hammarstrom L, Edvard Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338(8760):162\u20136.","journal-title":"Lancet"},{"key":"1952_CR10","first-page":"277","volume":"6","author":"L Kobrynski","year":"2012","unstructured":"Kobrynski L. Subcutaneous Immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics. 2012;6:277\u201387.","journal-title":"Biologics"},{"key":"1952_CR11","unstructured":"US Food and Drug Administration. Approval letter for Vivaglobin January 9, 2006. 2006.\u00a0https:\/\/wayback.archive-it.org\/7993\/20170723030023\/https:\/\/www.fda.gov\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/ucm070367.htm. Accessed 16 Apr 2025."},{"key":"1952_CR12","unstructured":"US Food and Drug Administration. Immune globulins: US food and drug administration. 2023.\u00a0https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/immune-globulins. Accessed 16 Apr 2025."},{"key":"1952_CR13","unstructured":"American Academy of Allergy Asthma & Immunology. Eight guiding principles for effective use of IVIG for patients with primary immunodeficiency. 2011. https:\/\/www.aaaai.org\/Aaaai\/media\/Media-Library-PDFs\/Practice%20Management\/Practice%20Tools\/IVIG-guiding-principles.pdf. Accessed 3 Oct 2023."},{"issue":"11\u201312","key":"1952_CR14","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1159\/000527655","volume":"107","author":"C von Achenbach","year":"2022","unstructured":"von Achenbach C, Hevia Hernandez G, von Gunten S. The choice between intravenous and subcutaneous immunoglobulins: aspects for consideration. Pharmacology. 2022;107(11\u201312):556\u201363.","journal-title":"Pharmacology"},{"issue":"2","key":"1952_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1023\/A:1006678312925","volume":"20","author":"HM Chapel","year":"2000","unstructured":"Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20(2):94\u2013100.","journal-title":"J Clin Immunol"},{"issue":"5","key":"1952_CR16","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s10875-010-9423-4","volume":"30","author":"JB Hagan","year":"2010","unstructured":"Hagan JB, Fasano MB, Spector S, Wasserman RL, Melamed I, Rojavin MA, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30(5):734\u201345.","journal-title":"J Clin Immunol"},{"issue":"7","key":"1952_CR17","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s11136-005-1746-x","volume":"14","author":"U Nicolay","year":"2005","unstructured":"Nicolay U, Haag S, Eichmann F, Herget S, Spruck D, Gardulf A. Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy. Qual Life Res. 2005;14(7):1683\u201391.","journal-title":"Qual Life Res"},{"issue":"1","key":"1952_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2004.02.002","volume":"112","author":"M Berger","year":"2004","unstructured":"Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112(1):1\u20137.","journal-title":"Clin Immunol"},{"issue":"4","key":"1952_CR19","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jaci.2004.07.045","volume":"114","author":"J Chinen","year":"2004","unstructured":"Chinen J, Shearer WT. Subcutaneous immunoglobulins: alternative for the hypogammaglobulinemic patient? J Allergy Clin Immunol. 2004;114(4):934\u20135.","journal-title":"J Allergy Clin Immunol"},{"issue":"03","key":"1952_CR20","first-page":"120","volume":"01","author":"A Chouksey","year":"2005","unstructured":"Chouksey A, Duff K, Wasserbauer N, Berger M. Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens. Allergy Asthma Clin Immunol. 2005;01(03):120.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1\u20134","key":"1952_CR21","first-page":"81","volume":"4","author":"A Gardulf","year":"1993","unstructured":"Gardulf A, Bj\u00f6rvell H, Gustafson R, Hammarstr\u00f6m L, Smith CI. Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody deficiency. Immunodeficiency. 1993;4(1\u20134):81\u20134.","journal-title":"Immunodeficiency"},{"issue":"2","key":"1952_CR22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1365-2249.1993.tb03380.x","volume":"92","author":"A Gardulf","year":"1993","unstructured":"Gardulf A, Bj\u00f6rvell H, Gustafson R, Hammarstr\u00f6m L, Smith CI. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol. 1993;92(2):200\u20134.","journal-title":"Clin Exp Immunol"},{"issue":"9081","key":"1952_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S0140-6736(05)62034-X","volume":"350","author":"R Gustafson","year":"1997","unstructured":"Gustafson R, Gardulf A, Granert C, Hansen S, Hammarstr\u00f6m L. Prophylactic therapy for selective IgA deficiency. Lancet. 1997;350(9081):865. https:\/\/doi.org\/10.1016\/S0140-6736(05)62034-X","journal-title":"Lancet"},{"issue":"2","key":"1952_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1046\/j.1365-2249.1998.00571.x","volume":"112","author":"U Sundin","year":"1998","unstructured":"Sundin U, Nava S, Hammarstr\u00f6m L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol. 1998;112(2):341\u20136.","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"1952_CR25","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s10875-016-0327-9","volume":"36","author":"D Suez","year":"2016","unstructured":"Suez D, Stein M, Gupta S, Hussain I, Melamed I, Paris K, et al. Efficacy, safety, and pharmacokinetics of a novel human immune globulin subcutaneous, 20% in patients with primary immunodeficiency diseases in North America. J Clin Immunol. 2016;36(7):700\u201312.","journal-title":"J Clin Immunol"},{"issue":"6","key":"1952_CR26","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s10875-016-0311-4","volume":"36","author":"J Heimall","year":"2016","unstructured":"Heimall J, Chen J, Church JA, Griffin R, Melamed I, Kleiner GI. Pharmacokinetics, safety, and tolerability of subcutaneous immune globulin injection (human), 10% caprylate\/chromatography purified (GAMUNEX\u00ae-C) in pediatric patients with primary immunodeficiency disease. J Clin Immunol. 2016;36(6):600\u20139.","journal-title":"J Clin Immunol"},{"issue":"4","key":"1952_CR27","first-page":"400","volume":"23","author":"S Kearns","year":"2017","unstructured":"Kearns S, Kristofek L, Bolgar W, Seidu L, Kile S. Clinical profile, dosing, and quality-of-life outcomes in primary immune deficiency patients treated at home with immunoglobulin G: data from the ideal patient registry. J Manag Care Spec Pharm. 2017;23(4):400\u20136.","journal-title":"J Manag Care Spec Pharm"},{"key":"1952_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fimmu.2019.00040","volume":"10","author":"RH Kobayashi","year":"2019","unstructured":"Kobayashi RH, Gupta S, Melamed I, Mandujano JF, Kobayashi AL, Ritchie B, et al. Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig\u00ae]) in the treatment of patients with primary immunodeficiencies. Front Immunol. 2019;10:40.","journal-title":"Front Immunol"},{"issue":"2","key":"1952_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1365-2249.2012.04594.x","volume":"169","author":"JS Orange","year":"2012","unstructured":"Orange JS, Belohradsky BH, Berger M, Borte M, Hagan J, Jolles S, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012;169(2):172\u201381.","journal-title":"Clin Exp Immunol"},{"key":"1952_CR30","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1002\/eji.201444700","volume":"44","author":"WAC Sewell","year":"2014","unstructured":"Sewell WAC, Kerr J, Behr-Gross ME, Peter HH. European consensus proposal for immunoglobulin therapies. Eur J Immunol. 2014;44:2207\u201314.","journal-title":"Eur J Immunol"},{"key":"1952_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3233\/PPL-2008-00198","volume":"10","author":"M Boyle","year":"2008","unstructured":"Boyle M, Scalchunes C. Impact of intervenous immunoglobulin (IVIG) treatment among patients with primary immunodeficiency diseases. Pharmaceut Policy Law. 2008;10:133\u201346.","journal-title":"Pharmaceut Policy Law"},{"issue":"3","key":"1952_CR32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","volume":"26","author":"HD Ochs","year":"2006","unstructured":"Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26(3):265\u201373.","journal-title":"J Clin Immunol"},{"issue":"3","key":"1952_CR33","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0091-6749(03)01781-0","volume":"112","author":"S Radinsky","year":"2003","unstructured":"Radinsky S, Bonagura VR. Subcutaneous Immunoglobulin infusion as an alternative to intravenous Immunoglobulin. J Allergy Clin Immunol. 2003;112(3):630\u20133.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1952_CR34","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0091-6749(98)70314-8","volume":"101","author":"ER Stiehm","year":"1998","unstructured":"Stiehm ER, Casillas AM, Finkelstein JZ, Gallagher KT, Groncy PM, Kobayashi RH, et al. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clin Immunol. 1998;101(6):848\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"16","key":"1952_CR35","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2217\/imt-2019-0159","volume":"11","author":"JW Sleasman","year":"2019","unstructured":"Sleasman JW, Lumry WR, Hussain I, Wedner HJ, Harris JB, Courtney KL, et al. Immune globulin subcutaneous, human \u2013 klhw 20% for primary humoral immunodeficiency: an open-label, phase III study. Immunotherapy. 2019;11(16):1371\u201386.","journal-title":"Immunotherapy"},{"issue":"Suppl 1Suppl 1","key":"1952_CR36","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/cei.12548","volume":"178","author":"M Rojavin","year":"2014","unstructured":"Rojavin M, Sidhu J, Pfister M, Hubsch A. Subcutaneous Immunoglobulin loading regimens for previously untreated patients with primary antibody deficiency. Clin Exp Immunol. 2014;178(Suppl 1Suppl 1):146\u20138.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"1952_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","volume":"26","author":"U Nicolay","year":"2006","unstructured":"Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26(1):65\u201372.","journal-title":"J Clin Immunol"},{"issue":"5","key":"1952_CR38","first-page":"504","volume":"67","author":"PB Daly","year":"1991","unstructured":"Daly PB, Evans JH, Kobayashi RH, Kobayashi AL, Ochs HD, Fischer SH, et al. Home-based Immunoglobulin infusion therapy: quality of life and patient health perceptions. Ann Allergy. 1991;67(5):504\u201310.","journal-title":"Ann Allergy"},{"issue":"1","key":"1952_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1477-7525-7-36","volume":"7","author":"M Bharmal","year":"2009","unstructured":"Bharmal M, Payne K, Atkinson M, Desrosiers M-P, Morisky D, Gemmen E. Validation of an abbreviated treatment satisfaction questionnaire for medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7(1):36.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"1952_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/oxfordjournals.pubmed.a024606","volume":"19","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson C, Layte R, Jenkinson D, Lawrence K, Petersen S, Paice C, et al. A shorter form health survey: can the SF-12 replicate results from the SF-36 in longitudinal studies? J Public Health Med. 1997;19(2):179\u201386.","journal-title":"J Public Health Med"},{"issue":"11","key":"1952_CR41","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0895-4356(98)00109-7","volume":"51","author":"B Gandek","year":"1998","unstructured":"Gandek B, Ware J, Aaronson N, Apolone G, Bjorner J, Brazier J, et al. Cross-validation of item selection and scoring for the SF-12 health survey in nine countries. J Clin Epidemiol. 1998;51(11):1171\u20138.","journal-title":"J Clin Epidemiol"},{"key":"1952_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.biologicals.2020.01.004","volume":"64","author":"W Alonso","year":"2020","unstructured":"Alonso W, Vandeberg P, Lang J, Yuziuk J, Silverstein R, Stokes K, et al. Immune globulin subcutaneous, human 20% solution (Xembify(R)), a new high concentration immunoglobulin product for subcutaneous administration. Biologicals. 2020;64:34\u201340.","journal-title":"Biologicals"},{"key":"1952_CR43","doi-asserted-by":"publisher","first-page":"108472","DOI":"10.1016\/j.intimp.2021.108472","volume":"104","author":"G Navarro-Mora","year":"2022","unstructured":"Navarro-Mora G, Alberti JJ, Mondou E, Vilardell D, Vicente Torres J, Ayguasanosa J, et al. Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases. Int Immunopharmacol. 2022;104:108472.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"1952_CR44","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1365-2249.2010.04195.x","volume":"161","author":"RL Wasserman","year":"2010","unstructured":"Wasserman RL, Irani AM, Tracy J, Tsoukas C, Stark D, Levy R, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate\/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol. 2010;161(3):518\u201326.","journal-title":"Clin Exp Immunol"},{"issue":"1\u20132","key":"1952_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s13554-014-0018-0","volume":"4","author":"J Sidhu","year":"2014","unstructured":"Sidhu J, Rojavin M, Pfister M, Edelman J. Enhancing patient flexibility of subcutaneous immunoglobulin g dosing: pharmacokinetic outcomes of various maintenance and loading regimens in the treatment of primary immunodeficiency. Biol Ther. 2014;4(1\u20132):41\u201355.","journal-title":"Biol Ther"},{"issue":"6","key":"1952_CR46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3810\/pgm.2013.11.2712","volume":"125","author":"CB Landersdorfer","year":"2013","unstructured":"Landersdorfer CB, Bexon M, Edelman J, Rojavin M, Kirkpatrick CM, Lu J, et al. Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency. Postgrad Med. 2013;125(6):53\u201361.","journal-title":"Postgrad Med"},{"issue":"6","key":"1952_CR47","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/cpdd.753","volume":"9","author":"MA Rojavin","year":"2020","unstructured":"Rojavin MA, Chapdelaine H, Tortorici MA, Praus M, Baheti G, Zhang Y, et al. Pharmacokinetic analysis of weekly versus biweekly igpro20 dosing in patients with primary immunodeficiency. Clin Pharmacol Drug Dev. 2020;9(6):664\u201370.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1952_CR48","doi-asserted-by":"publisher","first-page":"106005","DOI":"10.1016\/j.intimp.2019.106005","volume":"81","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Baheti G, Chapdelaine H, Hofmann J, Rojavin M, Tortorici M, et al. Population pharmacokinetic analysis of weekly and biweekly IgPro20 (Hizentra\u00ae) dosing in patients with primary immunodeficiency. Int Immunopharmacol. 2020;81:106005.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"1952_CR49","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s10875-018-0528-5","volume":"38","author":"A Vultaggio","year":"2018","unstructured":"Vultaggio A, Azzari C, Ricci S, Martire B, Palladino V, Gallo V, et al. Biweekly Hizentra(\u00ae) in primary immunodeficiency: a multicenter, observational cohort study (IBIS). J Clin Immunol. 2018;38(5):602\u20139.","journal-title":"J Clin Immunol"},{"issue":"2","key":"1952_CR50","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/ped.2018.0967","volume":"32","author":"C Canessa","year":"2019","unstructured":"Canessa C, Gallo V, Pignata C, Trizzino A, Graziani S, Martire B, et al. Subcutaneous Immunoglobulin 20% every two weeks in pediatric patients with primary immunodeficiencies: subcohort analysis of the ibis study. Pediatr Allergy Immunol Pulmonol. 2019;32(2):70\u20135.","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"issue":"1","key":"1952_CR51","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.clim.2011.06.002","volume":"141","author":"S Jolles","year":"2011","unstructured":"Jolles S, Bernatowska E, de Gracia J, Borte M, Cristea V, Peter HH, et al. Efficacy and safety of Hizentra((R)) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol. 2011;141(1):90\u2013102.","journal-title":"Clin Immunol"},{"issue":"4","key":"1952_CR52","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaci.2009.07.051","volume":"124","author":"S Desai","year":"2009","unstructured":"Desai S, Chouksey A, Poll J, Berger M. A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously. J Allergy Clin Immunol. 2009;124(4):854\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1952_CR53","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s10875-011-9557-z","volume":"31","author":"M Borte","year":"2011","unstructured":"Borte M, Pac M, Serban M, Gonzalez-Quevedo T, Grimbacher B, Jolles S, et al. Efficacy and safety of hizentra(R), a new 20% Immunoglobulin Preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. J Clin Immunol. 2011;31(5):752\u201361.","journal-title":"J Clin Immunol"},{"issue":"6","key":"1952_CR54","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1007\/s10875-023-01509-4","volume":"43","author":"S Gupta","year":"2023","unstructured":"Gupta S, DeAngelo J, Melamed I, Walter JE, Kobayashi AL, Bridges T, et al. Subcutaneous immunoglobulin 16.5% (Cutaquig\u00ae) in primary immunodeficiency disease: safety, tolerability, efficacy, and patient experience with enhanced infusion regimens. J Clin Immunol. 2023;43(6):1414\u201325.","journal-title":"J Clin Immunol"},{"issue":"3","key":"1952_CR55","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s40261-020-00885-8","volume":"40","author":"A Pecoraro","year":"2020","unstructured":"Pecoraro A, Ricci S, Vultaggio A, Boggia GM, Spadaro G. Correlations among subcutaneous immunoglobulin dosage, immunoglobulin g serum pre-infusional levels and body mass index in primary antibody deficiency patients: a pooled analysis from the SHIFT\/IBIS studies. Clin Drug Investig. 2020;40(3):279\u201386.","journal-title":"Clin Drug Investig"},{"key":"1952_CR56","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3389\/fimmu.2020.00981","volume":"11","author":"E Wiesik-Szewczyk","year":"2020","unstructured":"Wiesik-Szewczyk E, Soldacki D, Paczek L, Jahnz-Rozyk K. Facilitated subcutaneous immunoglobulin replacement therapy in clinical practice: a two center, long-term retrospective observation in adults with primary immunodeficiencies. Front Immunol. 2020;11:981.","journal-title":"Front Immunol"},{"issue":"1","key":"1952_CR57","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","volume":"137","author":"JS Orange","year":"2010","unstructured":"Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21\u201330.","journal-title":"Clin Immunol"},{"issue":"4","key":"1952_CR58","doi-asserted-by":"publisher","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","volume":"117","author":"J Orange","year":"2006","unstructured":"Orange J, Hossny E, Weiler C, Ballow M, Berger M, Bonilla F, et al. Use of intravenous Immunoglobulin in human disease: A review of evidence by members of the primary immunodeficiency committee of the American academy of Allergy, asthma and immunology. J Allergy Clin Immunol. 2006;117(4):S525\u201353.","journal-title":"J Allergy Clin Immunol"},{"issue":"8541","key":"1952_CR59","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(87)90494-6","volume":"329","author":"CM Roifman","year":"1987","unstructured":"Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinemia and chronic lung disease. Lancet. 1987;329(8541):1075\u20137.","journal-title":"Lancet"},{"issue":"3","key":"1952_CR60","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s10875-021-01181-6","volume":"42","author":"M Santamaria","year":"2022","unstructured":"Santamaria M, Neth O, Douglass JA, Krivan G, Kobbe R, Bernatowska E, et al. A multi\u2013center, open\u2013label, single\u2013arm trial to evaluate the efficacy, pharmacokinetics, and safety and tolerability of IGSC 20% in Subjects with primary immunodeficiency. Subjects with primary immunodeficiency. J Clin Immunol. 2022;42(3):500\u201311.","journal-title":"J Clin Immunol"},{"issue":"5","key":"1952_CR61","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s10875-023-01436-4","volume":"43","author":"K Rosenbach","year":"2023","unstructured":"Rosenbach K, Park M, Sanchirico M, Nwose O, Paris K. Real-world evidence of tolerability of 20% subcutaneous immunoglobulin treatment. J Clin Immunol. 2023;43(5):912\u201320.","journal-title":"J Clin Immunol"},{"issue":"3","key":"1952_CR62","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40261-015-0270-1","volume":"35","author":"A Vultaggio","year":"2015","unstructured":"Vultaggio A, Azzari C, Milito C, Finocchi A, Toppino C, Spadaro G, et al. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study. Clin Drug Investig. 2015;35(3):179\u201385.","journal-title":"Clin Drug Investig"},{"issue":"6","key":"1952_CR63","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/01.all.0000246619.49494.41","volume":"6","author":"A Gardulf","year":"2006","unstructured":"Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2006;6(6):434\u201342.","journal-title":"Curr Opin Allergy Clin Immunol"}],"updated-by":[{"DOI":"10.1007\/s10875-026-01983-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000}}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-025-01952-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-025-01952-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-025-01952-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:01:53Z","timestamp":1777309313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-025-01952-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1952"],"URL":"https:\/\/doi.org\/10.1007\/s10875-025-01952-5","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was updated to correct an error in the Figure 1 caption. The caption incorrectly described the dosing regimen for treatment-experienced patients during period 1 as daily, when it was in fact weekly.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10875-026-01983-6","URL":"https:\/\/doi.org\/10.1007\/s10875-026-01983-6","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CH, IH, DM, TB, HJW and MS report no competing interests. WL reports that his institution has received research grants from CSL Behring, KalVista, Ionis, Pharvaris and Astria. WL has received consulting fees from BioCryst. CSL Behring, Astria, KalVista, Intellia, Pharvaris, Pharming and Takeda and honoraria from Pharming, CSL Behring, Takeda and Biocryst. WL has served on advisory boards for Biocryst, CSL Behring, Astria, KalVista, Intellia, Pharvaris, Pharming, Takeda and the medical advisory board of the US Hereditary Angioedema Association. MP reports serving as a speaker for CSL Behring and serving on advisory boards for Takeda. EM, NN-K, KH, MQC, and JO are employees of Grifols.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}